All Title Author
Keywords Abstract

The Atherogenic Dyslipidemia Ratio Log (Tg)/Hdl-C Was Not Associated with Urinary Albumin Excretion Rate (Uaer) and Increased Cardiovascular Risk in Black Patients with Type 2 Diabetes

DOI: 10.4236/wjcd.2016.61003, PP. 14-20

Keywords: Log (TG)/HDL-C, Cardiovascular Risk, Type 2 Diabetes, Black Africans

Full-Text   Cite this paper   Add to My Lib


Objective: The objective is to assess the relationship of Log (TG)/HDL-c as surrogate estimate of atherogenic dyslipidemia with urinary albumin excretion rate and cardiovascular risk among black patients with type 2 diabetes. Patients and methods: A post-hoc analysis of data from 181 type 2 diabetes patients enrolled in a cross-sectional study of urinary albumin excretion rate seen at a tertiary healthcare. Microalbuminuria and macroalbuminuria were defined as ACR 30 - 299.9 mg/g and ACR ≥ 300 mg/g, respectively. Quartiles of Log (TG)/HDL-c were used as surrogate estimates of atherogenic dyslipidemia. Cardiovascular risk was assessed using WHO chart for estimation of CV risk in low and middle income countries. Comparisons across Log (TG)/HDL-c quartiles were performed using one way ANOVA and Chi square for trend as appropriate. P < 0.05 defined the level of statistical significance. Results: A high prevalence (69%) of atherogenic dyslipidemia (AD) was observed in the present case series of Black Africans with type 2 diabetes. Average total cholesterol levels showed significant (p = 0.010) trends towards lower values across quartiles of Log (TG)/ HDL-c. No significant trends were observed for average UAER and cardiovascular risk across quartiles of Log (TG)/HDL-c. Conclusion: Log (TG)/HDL-c as a surrogate estimate of atherogenic failed to predict cardiovascular risk in the present case series of black patients with type 2 diabetes.


[1]  Naidoo, D.P. (2002) The Link between Microalbuminuria, Endothelial Dysfunction and Cardiovascular Disease in Diabetes. Cardiovasc J South Afr, 13, 194-199.
[2]  Hamilton, S.J. and Watts, G.F. (2013) Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Trials. The Review of Diabetic Studies, 10, 191-203.
[3]  Agouridis, A.P., Rizos, C.V., Elisaf, M.S. and Filippatos, T.D. (2013) Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia? The Review of Diabetic Studies, 10, 171-190.
[4]  Pandeya, A., Sharma, M., Regmi, P., Basukala, A. and Lamsal, M.S. (2002) Pattern of Dyslipidemia and Evaluation of Non-HDL-c as a Marker of Risk Factor for Cardiovascular Disease in Type 2 Diabetes Mellitus. Nepal Med Coll J, 14, 278-282.
[5]  American Diabetes Association: Standards of Medical Care in Diabetes-2009. Diabetes Care, 32, S13-S61.
[6]  Charlton-Menys, V., Betteridge, D.J., Colhoun, H., Fuller, J., France, M., Hitman, G.A., et al. (2009) Target of Statin Therapy; LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CRDS). Clinical Chemistry, 55, 473-480.
[7]  Wanner, C. and Krane, V. (2011) Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. Kidney and Blood Pressure Research, 34, 209-217.
[8]  Pang, J. and Chan, G.F. (2014) Origin and Therapy for Hypertriglyceridemia in Type 2 Diabetes. World Journal of Diabetes, 5, 165-175.
[9]  Bosomworth, N.J. (2013) Approach to Identifying and Managing Atherogenic Dyslipidemia. A Metabolic Consequence of Obesity and Insulin Resistance. Canadian Family Physician, 59, 1169-1180.
[10]  Ginsberg, H.N. and MacCallun, P.R. (2009) The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: II. Therapeutic Management of Atherogenic Dyslipidemia. Journal of Clinical Hypertension, 11, 520-527.
[11]  de Boer, I.H., Astor, H.K., Kramer, H., Palmas, W., Rudser, K., Seliger, S., et al. (2008) Mild Elevations in Urine Albumin Excretion Are Associated with Atherogenic Lipid Abnormalities in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 197, 407-414.
[12]  Tseng, C.H. (2009) Differential Dyslipidemia with Albuminuria in Type 2 Diabetes Patients in Taiwan. Clinical Biochemistry, 42, 1019-1024.
[13]  Tseng, C.H. (2005) Lipid Abnormalities Associated with Urinary Albumin Excretion Rate (UAER) in Type 2 Diabetic Patients. Kidney International, 67, 1547-1553.
[14]  Tennebaum, A. and Fisman, E.Z. (2012) Fibrates Are an Essential Part of Modern Anti-Dyslipidemic Arsenal: Spotlight on Atherogenic Dyslipidemia and Residual Risk Reduction. Cardiovascular Diabetology, 11, 125.
[15]  Hermans, P.H., Ahn, A.A. and Rousseau, M.F. (2012) The Atherogenic Dyslipidemia Ratio [Log(TG)/HDL-c] Is Associated with Residual Vascular Risk, Beta-Cell Function Loss and Microangiopathy in Type 2 Diabetes Females. Lipids in Health and Disease, 11, 132.
[16]  Hermans, M.P., Ahn, S.A. and Rousseau, M.F. (2010) [log(TG)/HDL-c] Is Related to Both Residual Cardiometabolic Risk and B-Cell Function Loss in Type 2 Diabetes Males. Cardiovascular Diabetology, 9, 88.
[17]  Onat, A., Can, G., Kaya, H. and Hergenc, G. (2010) Atherogenic Index of Plasma (Log10 Triglyceride/High-Density Lipoprotein-Cholesterol) Predicts High Blood Pressure, Diabetes, and Vascular Events. Journal of Clinical Lipidology, 4, 89-98.
[18]  Sirimarco, G., Labreuche, J., Bruckert, E., Goldstein, L.B., Fox, K.M., Rothwell, P.M., et al. (2014) Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients. Stroke, 45, 1429-1436.
[19]  Jisieike-Onuigbo, N.N., Unuigbe, E.I., Kalu, O.A., Oguejiofor, C.O. and Onuigbo, P.C. (2011) Prevalence of Dyslipidemia among Adult Diabetic Patients with Overt Diabetic Nephropathy in Anambra State South-East Nigeria. Nigerian Journal of Clinical Practice, 14, 171-175.
[20]  Risassi, J.R., Nseka, M.N., Mvitu, M., Muyer, M.T., Kimenyembo, W., Mandja, M., Bieleli, E.O., Mapatano, M.A., Lepira, F.B., Sumaili, E.K., Kaimbo, W.K., Nge, O., Buntinx, F. and Muls, E. (2010) Albuminuria during the Screening for Diabetes in a Semi Rural Area (Kisantu City, DR Congo). Nephrology & Therapeutics, 6, 513-519.
[21]  Bieleli, E. (1999) Study of Plasma Cholesterol and Lipoproteins among Adult Congelese Patients with Diabetes Mellitus. Thesis, School of Medicine, University of Kinshasa, Kinshasa. (In French)
[22]  Bennett, P.H., Haffner, S., Kasiske, B.L., Keane, W.F., Mogensen, C.E., Parving, H.H., et al. (1995) Screening and Management of Microalbuminuria in Patients with Diabetes Mellitus: Recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. American Journal of Kidney Diseases, 25, 107-112.
[23]  Friedelwald, W.T., Levy, R.I. and Fredrickson, D.S. (1972) Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge. Clinical Chemistry, 18, 499-502.
[24]  Foro Dislipidemia Aterogénica (2013) Consenso multidisciplinar sobre dislipidemia aterogénica. Atherogenic Dyslipidemia: A Multidisciplinary Consensus Panel. Clínica e Investigación en Arteriosclerosis, 25, 83-91.
[25]  Mendis, S., Puska, P. and Norrving, B. (Eds.) (2011) Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization in Collaboration with the World Heart Federation and the World Stroke Organization, Geneva.
[26]  Wang, S.H., Wang, L., Zhou, Y., Guo, Y.J., Yuan, Y., Li, F.F., et al. (2012) Prevalence and Control of Dyslipidaemia among Diabetic Patients with Microalbuminuria in a Chinese Hospital. Diabetes & Vascular Disease Research, 10, 169-178.
[27]  Yu, S.S.K., Darleen, C., Castillo, D.C., Courville, A.B. and Sumner, A.E. (2012) The Triglyceride Paradox in People of African Descent. Metabolic Syndrome and Related Disorders, 10, 77-82.
[28]  Nwagha, U.I., Ikekpeazu, E.J., Ejezie, F.E., Neboh, E.E. and Maduka, I.C. (2010) Atherogenic Index of Plasma as Auseful Predictor of Cardiovascular Risk among Postmenopausal Women in Enugu, Nigeria. African Health Sciences, 10, 248-252.
[29]  Knight, M.G., Goedecke, J.H., Ricks, M., Evans, J., Levitt, N.S., Tulloch-Reid, M.K. and Sumner, A.E. (2011) The TG/HDL-C Ratio Does Not Predict Insulin Resistance in Overweight Women of African Descent: A Study of South African, African American and West African Women. Ethnicity & Disease, 21, 490-494.
[30]  Zoppini, G., Negri, C., Stoico, V., Casali, S., Pichiri, I. and Bonora, I. (2012) Triglyceride-High-Density Lipoprotein Is Associated with Microvascular Complications in Type 2 Diabetes Mellitus. Metabolism—Clinical and Experimental, 61, 22-29.
[31]  Sumner, A.E., Finley, K.B., Genovese, D.J., Criqui, M.H. and Boston, R.C. (2005) Fasting Triglyceride and the Triglyceride-HDL Cholesterol Ratio Are Not Markers of Insulin Resistance in African Americans. Archives of Internal Medicine, 165, 1395-1400.
[32]  Sumner, A.E., Harman, J.L., Buxbaum, S.G., Miller, B.V., Tambay, A.V., Wyatt, S.B., et al. (2010) The Triglyceride/High-Density Lipoprotein Cholesterol Ratio Fails to Predict Insulin Resistance in African-American Women: An Analysis of Jackson Heart Study. Metabolic Syndrome and Related Disorders, 8, 511-514.
[33]  Goedecke, J.H., Utzschneider, K., Faulenbach, M.V., et al. (2010) Ethnic Differences in Serum Lipoproteins and Their Determinants in South African Women. Metabolism—Clinical and Experimental, 59, 1341-1350.
[34]  Osei, K. (2010) Metabolic Syndrome in Blacks: Are the Criteria Right? Current Diabetes Reports, 10, 199-208.
[35]  Kim-Dorner, S.J., Deuster, P.A., Zeno, S.A., Remaley, A.T. and Poth, M. (2010) Should Triglycerides and the Triglycerides to High-Density Lipoprotein Cholesterol Ratio Be Used as Surrogates for Insulin Resistance? Metabolism— Clinical and Experimental, 59, 299-304.


comments powered by Disqus